Drug Trial Radar · NCT04214288
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Actual
Start
Apr 22, 2020
Primary completion
Aug 30, 2022
Study completion Jun 16, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
Conditions
- Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833Drug
Dosage formulation: AZD9833 tablets will be administered orally.
FulvestrantDrug
Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months)
Locations
85 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Long Beach, California
Research Site
Fort Myers, Florida
Research Site
St. Petersburg, Florida
Research Site
Lincoln, Nebraska
Research Site
Canton, Ohio
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Eagle River, Wisconsin
Research Site
Brasschaat, Belgium
Research Site
Charleroi, Belgium
Research Site
Ghent, Belgium
Research Site
Haine-Saint-Paul, Belgium
Research Site
Leuven, Belgium
Research Site
Libramont-Chevigny, Belgium
Research Site
Namur, Belgium
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Paris, France
Research Site
Vandœuvre-lès-Nancy, France
Research Site
Batumi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Berlin, Germany
Research Site
Düsseldorf, Germany
Research Site
Essen, Germany
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Kaposvár, Hungary
Research Site
Kecskemét, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Pécs, Hungary
Research Site
Szeged, Hungary
Research Site
Jerusalem, Israel
Research Site
Jerusalem, Israel
Research Site
Nahariya, Israel
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.